Cargando…

Vitamin C: should we supplement?

PURPOSE OF REVIEW: Hypovitaminosis C and vitamin C deficiency are very common in critically ill patients due to increased needs and decreased intake. Because vitamin C has pleiotropic functions, deficiency can aggravate the severity of illness and hamper recovery. RECENT FINDINGS: Vitamin C is a key...

Descripción completa

Detalles Bibliográficos
Autores principales: Spoelstra-de Man, Angélique M.E., Elbers, Paul W.G., Oudemans-Van Straaten, Heleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039380/
https://www.ncbi.nlm.nih.gov/pubmed/29864039
http://dx.doi.org/10.1097/MCC.0000000000000510
_version_ 1783338661449826304
author Spoelstra-de Man, Angélique M.E.
Elbers, Paul W.G.
Oudemans-Van Straaten, Heleen M.
author_facet Spoelstra-de Man, Angélique M.E.
Elbers, Paul W.G.
Oudemans-Van Straaten, Heleen M.
author_sort Spoelstra-de Man, Angélique M.E.
collection PubMed
description PURPOSE OF REVIEW: Hypovitaminosis C and vitamin C deficiency are very common in critically ill patients due to increased needs and decreased intake. Because vitamin C has pleiotropic functions, deficiency can aggravate the severity of illness and hamper recovery. RECENT FINDINGS: Vitamin C is a key circulating antioxidant with anti-inflammatory and immune-supporting effects, and a cofactor for important mono and dioxygenase enzymes. An increasing number of preclinical studies in trauma, ischemia/reperfusion, and sepsis models show that vitamin C administered at pharmacological doses attenuates oxidative stress and inflammation, and restores endothelial and organ function. Older studies showed less organ dysfunction when vitamin C was administered in repletion dose (2–3 g intravenous vitamin C/day). Recent small controlled studies using pharmacological doses (6–16 g/day) suggest that vitamin C reduces vasopressor support and organ dysfunction, and may even decrease mortality. SUMMARY: A short course of intravenous vitamin C in pharmacological dose seems a promising, well tolerated, and cheap adjuvant therapy to modulate the overwhelming oxidative stress in severe sepsis, trauma, and reperfusion after ischemia. Large randomized controlled trials are necessary to provide more evidence before wide-scale implementation can be recommended.
format Online
Article
Text
id pubmed-6039380
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-60393802018-07-20 Vitamin C: should we supplement? Spoelstra-de Man, Angélique M.E. Elbers, Paul W.G. Oudemans-Van Straaten, Heleen M. Curr Opin Crit Care METABOLIC SUPPORT: Edited by Arthur R.H. van Zanten PURPOSE OF REVIEW: Hypovitaminosis C and vitamin C deficiency are very common in critically ill patients due to increased needs and decreased intake. Because vitamin C has pleiotropic functions, deficiency can aggravate the severity of illness and hamper recovery. RECENT FINDINGS: Vitamin C is a key circulating antioxidant with anti-inflammatory and immune-supporting effects, and a cofactor for important mono and dioxygenase enzymes. An increasing number of preclinical studies in trauma, ischemia/reperfusion, and sepsis models show that vitamin C administered at pharmacological doses attenuates oxidative stress and inflammation, and restores endothelial and organ function. Older studies showed less organ dysfunction when vitamin C was administered in repletion dose (2–3 g intravenous vitamin C/day). Recent small controlled studies using pharmacological doses (6–16 g/day) suggest that vitamin C reduces vasopressor support and organ dysfunction, and may even decrease mortality. SUMMARY: A short course of intravenous vitamin C in pharmacological dose seems a promising, well tolerated, and cheap adjuvant therapy to modulate the overwhelming oxidative stress in severe sepsis, trauma, and reperfusion after ischemia. Large randomized controlled trials are necessary to provide more evidence before wide-scale implementation can be recommended. Lippincott Williams & Wilkins 2018-08 2018-06-01 /pmc/articles/PMC6039380/ /pubmed/29864039 http://dx.doi.org/10.1097/MCC.0000000000000510 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle METABOLIC SUPPORT: Edited by Arthur R.H. van Zanten
Spoelstra-de Man, Angélique M.E.
Elbers, Paul W.G.
Oudemans-Van Straaten, Heleen M.
Vitamin C: should we supplement?
title Vitamin C: should we supplement?
title_full Vitamin C: should we supplement?
title_fullStr Vitamin C: should we supplement?
title_full_unstemmed Vitamin C: should we supplement?
title_short Vitamin C: should we supplement?
title_sort vitamin c: should we supplement?
topic METABOLIC SUPPORT: Edited by Arthur R.H. van Zanten
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039380/
https://www.ncbi.nlm.nih.gov/pubmed/29864039
http://dx.doi.org/10.1097/MCC.0000000000000510
work_keys_str_mv AT spoelstrademanangeliqueme vitamincshouldwesupplement
AT elberspaulwg vitamincshouldwesupplement
AT oudemansvanstraatenheleenm vitamincshouldwesupplement